Table 1 Patient characteristics
Canagliflozin group (n = 75) | Teneligliptin group (n = 70) | p value | |
|---|---|---|---|
Sex (male), n (%) | 51 (68.0%) | 47 (67.1%) | 1.000 |
Age, mean ± SD | 57.2 ± 11.5 | 55.2 ± 11.4 | 0.5277 |
Height (cm), mean ± SD | 165.5 ± 9.2 | 165.5 ± 9.5 | 0.9984 |
Body weight (kg), mean ± SD | 79.0 ± 15.2 | 79.2 ± 16.7 | 0.7848 |
BMI, mean ± SD | 28.7 ± 4.7 | 28.8 ± 4.8 | 0.854 |
HbA1c (%), mean ± SD | 7.7 ± 0.6 | 7.8 ± 0.8 | 0.3706 |
HDL-C (mg/dL), mean ± SD | 52.1 ± 12.1 | 53.6 ± 11.4 | 0.3532 |
Triglyceride (mg/dL), mean ± SD | 202.1 ± 195.0 | 169.7 ± 115.5 | 0.5336 |
Systolic blood pressure (mmHg), mean ± SD | 140.7 ± 19.0 | 137.8 ± 14.7 | 0.4580 |
Diastolic blood pressure (mmHg), mean ± SD | 83.4 ± 10.5 | 82.7 ± 9.9 | 0.7454 |
Dyslipidemia, n (%) | 34 (45.3%) | 31 (44.4%) | 1.000 |
Hypertension, n (%) | 55 (73.3%) | 50 (71.4%) | 0.8536 |
Duration of diabetes mellitus (years), mean ± SD | 5.9 ± 4.9 | 6.7 ± 6.3 | 0.7889 |
Metformin treatment, n (%) | 44 (58.7%) | 44 (62.9%) | 0.6148 |